US FDA lifts partial clinical hold on BioNTech cancer drug study-March 2024-www.financetom.com

US FDA lifts partial clinical hold on BioNTech cancer drug study

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

US FDA lifts partial clinical hold on BioNTech cancer drug study

Dec 13, 2024 1:33 PM

Dec 13 (Reuters) - BioNTech SE said on Friday it has been informed by its

partner OncoC4 that the U.S. Food and Drug Administration has lifted the partial clinical hold

on its late-stage trial studying its drug for a type of lung cancer.

Previous page： Trump administration to pilot coverage of weight-loss drugs under Medicare and Medicaid, Washington Post reports Next page： Google agrees $36 million fine for anti-competitive deals with Australia telcos

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Trump administration to pilot coverage of weight-loss drugs under Medicare and Medicaid, Washington Post reports

Aug 1, 2025

Aug 1 (Reuters) - The Trump administration is planning an experiment to cover weight-loss drugs under Medicare and Medicaid, the Washington Post reported on Friday. ...

Google agrees $36 million fine for anti-competitive deals with Australia telcos

Aug 17, 2025

SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...

AirSculpt Q2 revenue falls more than expected, CFO to retire

Aug 1, 2025

Overview * AirSculpt ( AIRS ) Q2 revenue declines 13.7%, missing analyst expectations, per LSEG data * Adjusted EBITDA for Q2 beats analyst estimates, indicating operational efficiency * Co announces CFO Dennis Dean's retirement, pending successor appointment Outlook * Company affirms 2025 revenue guidance of $160 mln to $170 mln * AirSculpt ( AIRS ) expects 2025 adjusted EBITDA of...

Canada's Fortis Q2 net earnings rise

Aug 1, 2025

Overview * Fortis ( FTS ) Q2 net earnings rise to C$384 mln, driven by rate base growth * Capital expenditures reach C$2.9 bln in H1, supporting C$5.2 bln annual plan * Co reports 34% reduction in GHG emissions compared to 2019 levels Outlook * Fortis ( FTS ) expects midyear rate base to grow from C$39 bln in 2024...